Table 1 Baseline characteristics of the study population
Cohorts | 0.5 mg/kg (N = 3) | 1 mg/kg (N = 3) | 2 mg/kg (N = 3) | 3 mg/kg (N = 3) | 5 mg/kg (N = 5) | Total (N = 17) |
|---|---|---|---|---|---|---|
Age (years) | ||||||
Median | 64 | 64 | 64 | 72 | 60 | 64 |
Q1, Q3 | 53, 72 | 62, 65 | 54, 67 | 39, 74 | 56, 62 | 56, 67 |
Sex | ||||||
Female | 2 (66.7%) | 3 (100%) | 1 (33.3%) | 2 (66.7%) | 3 (60%) | 11 (64.7%) |
Male | 1 (33.3%) | 0 | 2 (66.7%) | 1 (33.3%) | 2 (40%) | 6 (35.3%) |
Body weight (kg) | ||||||
Median | 70.0 | 61.0 | 67.0 | 58.2 | 68.2 | 68.0 |
Q1, Q3 | 60.5, 76.5 | 58.0, 62.0 | 63.5, 99.0 | 43.6, 72.0 | 68.2, 108.0 | 61.0, 72.0 |
Solid tumors occurring in the enrolled population | ||||||
Breast cancer | 2 (66.7%) | 0 | 1 (33.3%) | 1 (33.3%) | 1 (20%) | 5 (29.4%) |
Colorectal cancer | 1 (33.3%) | 2 (66.7%) | 0 | 0 | 1 (20%) | 4 (23.5%) |
Gastric cancer | 0 | 0 | 0 | 0 | 1 (20%) | 1 (5.9%) |
Glioblastoma | 0 | 0 | 0 | 1 (33.3%) | 0 | 1 (5.9%) |
Hepatocellular carcinoma | 0 | 0 | 0 | 0 | 1 (20%) | 1 (5.9%) |
Ovarian cancer | 0 | 1 (33.3%) | 0 | 0 | 0 | 1 (5.9%) |
Pancreatic cancer | 0 | 0 | 2 (66.7%) | 0 | 1 (20%) | 3 (17.6%) |
Peritoneal mesothelioma | 0 | 0 | 0 | 1 (33.3%) | 0 | 1 (5.9%) |
ECOG performance status | ||||||
0 | 3 (100%) | 0 | 2 (66.7%) | 0 | 5 (100%) | 10 (58.8%) |
1 | 0 | 3 (100%) | 0 | 1 (33.3%) | 0 | 4 (23.5%) |
2 | 0 | 0 | 1 (33.3%) | 2 (66.7%) | 0 | 3 (17.6%) |